Coverage: The Meridian legal market record (editorial).
Ownership of a portfolio of pharmaceutical brands transfers for MENA territories that include North African markets inside Hikma's footprint.
| Record ID | TX-AFR-2024-0047 |
|---|---|
| Record type | Commercial IP transaction |
| Transaction type | Trade mark assignment, IP portfolio acquisition, Licence extension |
| IP rights | trade mark, regulatory data |
| Status | Signed |
| Qualifying date | 2024-12-19 |
| Sector | Life sciences · Branded pharmaceuticals |
| African markets | Egypt, Morocco |
| Licensed territory | Not separately described in the sources reviewed. |
| Disclosed value | Not disclosed in the sources reviewed. |
| Evidence | Primary source, single · 1 source(s) |
| Last verified | 2026-10-25 |
Parties
- Hikma Pharmaceuticals PLC (United Kingdom): acquirer, assignee, licensee
- Takeda Pharmaceuticals International AG (Switzerland): seller, assignor, licensor
Key terms
- Interest: ownership (assignment of licensed rights); Exclusivity: Ownership in the territories; Territorial scope: Select MENA territories
Sources
- Hikma acquires the rights to a portfolio of Takeda brands for the MENA region, Hikma Pharmaceuticals, 2024-12-19
Part of The Meridian’s Africa IP database. Counts, market breakdowns and rankings are derived from published records only; a record counts once. Corrections: submit evidence.


